(Q50559084)

English

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy

scientific article published on May 15, 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy (English)

reason for preferred rank

most precise value

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20669224

13 June 2024

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Chao-Hung Hung

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Chuan-Mo Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Jing-Houng Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Tsung-Hui Hu

4

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Chien-Hung Chen

5

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Chih-Yun Lin

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Sheng-Nan Lu

7

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

language of work or name

0 references

publication date

1 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

15 May 2011

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20669224

13 June 2024

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.25585

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20669224

13 June 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.25585

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.25585

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ijc.25585

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

128

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

10

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

2344-2352

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Hepatitis C virus infection and incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Effect of diabetes mellitus on hepatic resection

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Outcome of liver transplantation in patients with diabetes mellitus: a case-control study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.25585

21 January 2018

Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma

3

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

4

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Treatment of chronic hepatitis C: a systematic review

6

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C

11

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C.

12

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis

25

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Fibrosis and disease progression in hepatitis C.

29

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection

40

1 reference

10.1002/IJC.25585

https://api.crossref.org/works/10.1002/IJC.25585

13 June 2024

Identifiers

10.1002/IJC.25585

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

release_6q2mdnsszfgkleqcorpmnokmla

1 reference

https://api.fatcat.wiki/v0/release/6q2mdnsszfgkleqcorpmnokmla

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/20669224

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50559084&oldid=2180225574"